| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/30/2003 | WO2003043569A2 Trans-10, cis-12 conjugated linoleic acid isomer for the treatment of diseases |
| 05/30/2003 | WO2003043445A2 Processed baby food with unsaturated fatty acids and/or nucleotides |
| 05/30/2003 | WO2003028697A3 Liposome loading with metal ions |
| 05/30/2003 | WO2003024391A3 Treatment and prevention of mucositis in cancer patients |
| 05/30/2003 | WO2003016917A3 Sodium channel regulators and modulators |
| 05/30/2003 | WO2003010141A3 Hepatitis c virus polymerase inhibitors with a heterobicyclic structure |
| 05/30/2003 | WO2003008448A3 Novel human proton-gated channels |
| 05/30/2003 | WO2003005998A3 A pharmaceutical composition comprising a nicotinic receptor partial antagonist and an antiemetic agent of modulating cholinergic function |
| 05/30/2003 | WO2003004006A3 Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis |
| 05/30/2003 | WO2003003976A3 Compositions for removing human cerumen |
| 05/30/2003 | WO2003002106A3 Use of tyrosine kinase inhibitions for treating allergic diseases |
| 05/30/2003 | WO2002102853A3 Cd4-specific antibody trx1 and uses therefor |
| 05/30/2003 | WO2002100890A3 Respiratory syncytial virus |
| 05/30/2003 | WO2002100328A3 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels |
| 05/30/2003 | WO2002098891A3 GADs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 05/30/2003 | WO2002094187A3 Novel use |
| 05/30/2003 | WO2002076501A3 Blood cell production via activation of the hemoglobin scavenger receptor |
| 05/30/2003 | WO2002076499A3 Combination treatment of pancreatic cancer |
| 05/30/2003 | WO2002070509A3 Antagonists of mcp-1 function and methods of use thereof |
| 05/30/2003 | WO2002066040A3 Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus |
| 05/30/2003 | WO2002064132A3 Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| 05/30/2003 | WO2002059293A3 Process and compositions for peptide, protein and peptidomimetic synthesis |
| 05/30/2003 | WO2002053728A9 Gene disruption methodologies for drug target discovery |
| 05/30/2003 | WO2002051868A3 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| 05/30/2003 | WO2002041897A3 Novel pharmaceutical compositions with anti-diabetic activity and method for preparing same |
| 05/30/2003 | WO2002041871A9 Composition comprising an imexon or derivatives thereof and lipids |
| 05/30/2003 | WO2002041827A9 Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| 05/30/2003 | WO2002031025A9 Biodegradable poly(beta-amino esters) and uses thereof |
| 05/30/2003 | WO2001091792A3 Anti-adhesion molecule antibody to treat inflammation and cancer by inducing the idiotypic network |
| 05/30/2003 | WO2001080823A3 Composition exhibiting enhanced formulation stability and delivery of tropical active ingredients |
| 05/30/2003 | WO2001052874A9 Intra-tumoral administration of il-12 encoding nucleic acid molecules |
| 05/30/2003 | CA2741542A1 Processed baby food with unsaturated fatty acids and/or nucleotides |
| 05/30/2003 | CA2506616A1 Substituted bicyclo[3.3.1]nonan-2,4,9-triones as pharmaceutical active ingredients |
| 05/30/2003 | CA2467930A1 Treatment of pml targeting jc virus agno |
| 05/30/2003 | CA2467908A1 Mfg-e8-l regulates phagocytic removal of apoptotic cells by macrophages |
| 05/30/2003 | CA2467559A1 Topical delivery of codrugs |
| 05/30/2003 | CA2467246A1 Composition and method for treatment of wounds |
| 05/30/2003 | CA2467206A1 Genes encoding g-protein coupled receptors and methods of use therefor |
| 05/30/2003 | CA2467104A1 A plant extract active as an immunostimulating agent |
| 05/30/2003 | CA2467095A1 Hypertonia treatment during the acute phase of a cerebrovascular accident |
| 05/30/2003 | CA2467035A1 Pharmaceutical product with an adsorbent |
| 05/30/2003 | CA2466986A1 Pharmaceutical formulation comprising bicalutamide |
| 05/30/2003 | CA2466916A1 New use for the treatment of gastroesophageal reflux disease |
| 05/30/2003 | CA2464867A1 Pharmaceutical and cosmetic compositions containing oxy group-bearing aromatic aldehydes |
| 05/30/2003 | CA2464542A1 Composition comprising and method of using angiopoietin-like protein 3 angptl3 |
| 05/30/2003 | CA2463790A1 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use |
| 05/29/2003 | US20030101466 Method for screening for agents against cancer using an immunosuppression animal model |
| 05/29/2003 | US20030100942 Hydrogel for the therapeutic treatment of aneurysms |
| 05/29/2003 | US20030100755 For example (2S, 3S, 5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-(2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl)amino-1,6-diphenylhexane; HIV therapy |
| 05/29/2003 | US20030100611 Delivery of gabapentin in a gastric retained dosage form for the treatment of epilepsy and other diseases |
| 05/29/2003 | US20030100594 Carbonic anhydrase inhibitor |
| 05/29/2003 | US20030100588 Indole-type inhibitors of p38 kinase |
| 05/29/2003 | US20030100582 Benzimidazole compounds for regulating IgE |
| 05/29/2003 | US20030100571 Such as 2-((6-(((4-(3,4-dimethoxyphenyl)methyl)amino)-7-ethyl-7H-purin-2-yl)amino) -4,5-methyl-N-phenyl-5-thiazole-carboxamide for treatment of lymphocyte mediated diseases such as transplant rejection and graft versus host disease |
| 05/29/2003 | US20030100570 Immunomodulation and effect on cell processes relating to serotonin family receptors |
| 05/29/2003 | US20030100567 Tyrosine kinase inhibitors |
| 05/29/2003 | US20030100563 Such as 7-((3R)-3-amino-4-(3,4-difluorophenyl)butanoyl)-2-(trifluoromethyl)-5,6,7,8 -tetrahydroimidazo(1,2-a)pyrazine dihydrochloride for treatment of insulin resistance disorders |
| 05/29/2003 | US20030100551 Production of apoptotic films for direct contact with tumors |
| 05/29/2003 | US20030100539 Metabotropic glutamate receptors (mGluR); treating fragile X, autism, mental retardation, schizophrenia and Down's Syndrome |
| 05/29/2003 | US20030100535 Administering a compound which binds to a galectin |
| 05/29/2003 | US20030100532 Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections |
| 05/29/2003 | US20030100517 For therapy of diseases involving fungal or suspected fungal infection, for immunomodulation or immunosuppression in conditions in which fungal or suspected fungal colonisation of e.g.skin plays a role |
| 05/29/2003 | US20030100510 Crystallized structure of type IV collagen NC1 domain hexamer |
| 05/29/2003 | US20030100507 Administering to a mammal therapeutically effective amount of opiate analgesic and endothelin antagonist for therapy and prophylaxis of pain |
| 05/29/2003 | US20030100504 Treatment and diagnosis of insulin-resistant states |
| 05/29/2003 | US20030100486 Inflammatory markers as tools in the detection and prevention of diabetes mellitus and as tools to aid in the selection of agents to be used for the prevention and treatment of diabetes |
| 05/29/2003 | US20030100484 Cell in which a urotensin II receptor is formed is contacted with a chemical compound; activity or quantity of a gene, or its gene product, from the cell from is determined, comparing with gene product of control cell |
| 05/29/2003 | US20030100478 Articles of manufacture |
| 05/29/2003 | US20030100034 Detection of modulators of cell activity; obtain cell, incubate with modulator, measure the concentration of target polypeptide, evaluate for cancer |
| 05/29/2003 | US20030100026 Stimulus-inducible protein kinase complex and methods of use therefor |
| 05/29/2003 | US20030100016 Complement C3 precursor biopolymer markers predictive of Alzheimers disease |
| 05/29/2003 | US20030100014 Apolipoprotein biopolymer markers predictive of type II diabetes |
| 05/29/2003 | US20030100010 Fibrinogen biopolymer Marker predictive of type II diabetes |
| 05/29/2003 | US20030100009 Inter alpha trypsin inhibitor biopolymer markers indicative of insulin resistance |
| 05/29/2003 | US20030099992 Genes associated with mast cell activation |
| 05/29/2003 | US20030099991 Detection of nucleotide sequences associated pain and nervous system disorders; obtain sample, incubate with probe, detect signal, recover nucleic acid, incubate with primer, amplify, evaluate for disorder |
| 05/29/2003 | US20030099971 Epidermal differentiation factor |
| 05/29/2003 | US20030099963 Nucleotied sequences coding polypeptide for use in the diagnosis and treatment of cancer |
| 05/29/2003 | US20030099765 Process for coating a surface of a stent |
| 05/29/2003 | US20030099756 Method of producing a processed kava product having an altered kavalactone distribution and processed kava products produced using the same |
| 05/29/2003 | US20030099747 Thickened oil compositions of edible oil |
| 05/29/2003 | US20030099732 Proteoglycan Compositions for Treating Prostate and Bladder Inflammatory Conditions |
| 05/29/2003 | US20030099727 Compositions and methods for reducing cytotoxicity and inhibiting angiogenesis |
| 05/29/2003 | US20030099726 Medicine comprises Echinacea phytochemicals and benzalkonium chloride in a sterile water solution; for therapy |
| 05/29/2003 | US20030099724 Compounds for prevention of diabetic retinopathy |
| 05/29/2003 | US20030099712 Therapeutic coating for an intravascular implant |
| 05/29/2003 | US20030099694 Method for the improvement of transport across adaptable semi-permeable barriers |
| 05/29/2003 | US20030099668 Comprises loading (transfection) immunogenic DNA oligonucleotides for enhanced lymphocyte response; genetic engineering |
| 05/29/2003 | US20030099661 Compositions and methods for the treatment of immune related diseases |
| 05/29/2003 | US20030099660 For regenerating tissues; antiaging agents; medical diagnosis; monitoring chemotherapy |
| 05/29/2003 | US20030099654 Comprises antibodies/proteins providing inhibition of prothrombinase; treatment and prevention of bacterial and viral infections, allograft/xenograft rejection, glomerulo-nephritis, cancer, gastrointestinal diseases, and fetal loss |
| 05/29/2003 | US20030099652 Novel human protein tyrosine kinase |
| 05/29/2003 | US20030099628 Preventing proliferation of a tumor, using heparinase III; use sequencing heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis |
| 05/29/2003 | US20030099627 Method for determining modulation of p110delta activity |
| 05/29/2003 | US20030099626 Mixture of various Aspergillus derived enzymes such as protease, lipase, amylase and cellulase and mineral cofactors such as calcium, zinc, manganese, and magnesium compounds |
| 05/29/2003 | US20030099609 Canine IL-4 nucleic acid molecules and uses thereof |
| 05/29/2003 | US20030099600 Metalloproteinase inhibitors for the treatment of respiratory diseases |
| 05/28/2003 | EP1314438A1 Anti-proliferative composition |
| 05/28/2003 | EP1314429A2 Use of an antiretroviral compound to manufacture a medicament for the treatment of sjogren's syndrome, systematic lupus erythematosis, scleroderma, or juvenile rheumatoid arthritis |
| 05/28/2003 | EP1314425A1 Medicinal compositions for preventing or treating heart failure |